Pathway to US Bronchitol Approval Clarified in FDA Response
Filed with ASX · · 2 pages · English
Earlier from Syntara
- US Advisory Committee Positive Recommendation on Bronchitol
- Quarterly Shareholder Update - March 2019
- Pharmaxis Commences Phase 1 LOX Clinical Trial
- Quarterly Shareholder Update - December 2018
- Pharmaxis Announces LOXL2 Program Phase 2 Ready
Later from Syntara
- Quarterly Shareholder Update - June 2019
- Pharmaxis Receives $6.2m R&D Tax Incentive
- FDA Provides Guidance on Bronchitol Approval Steps
- Quarterly Shareholder Update - September 2019
- Pharmaxis Business Plan Update
Follow Syntara into a list and get an email when it puts out news.
Follow Syntara